B Hirschel
Genital shedding of HIV after scheduled treatment interruption
Ananworanich J, Hirschel B, Ruxrungtham K, Cooper D, Jupimai T, Ubolyam S, Mahanontharit A, Chotnopparatpattara P, Chaithongwongwatthana S, Mangclaviraj S, Vernazza P, Kerr S, and the Staccato HIV-NAT Study Group. Genital shedding of HIV after scheduled treatment interruption. Int J STD AIDS 2011; 22:61-6.
Feb 1, 2011Genital shedding of HIV after scheduled treatment interruption
Feb 1, 2011Int J STD AIDS 2011; 22:61-6
Ananworanich J, Hirschel B, Ruxrungtham K, Cooper D A, Jupimai T, Ubolyam S, Mahanontharit A, Chotnopparatpattara P, Chaithongwongwatthana S, Mangclaviraj S, Vernazza Pietro, Kerr S J, and the Staccato HIV-NAT Study Group
Clinical relevance of cytomegalovirus viraemia(*,†)
El Amari E, Hirschel B, Bernasconi E, Hirsch H, Vernazza P, Cavassini M, Furrer H, Hasse B, Kaiser L, Calmy A, Yerly S, Combescure C, Swiss HIV Cohort Study. Clinical relevance of cytomegalovirus viraemia(*,†). HIV Med 2011; 12:394-402.
Jan 19, 2011Clinical relevance of cytomegalovirus viraemia(*,†)
Jan 19, 2011HIV Med 2011; 12:394-402
El Amari E Boffi, Hirschel B, Bernasconi E, Hirsch Hh, Vernazza Pietro, Cavassini M, Furrer H, Hasse B, Kaiser L, Calmy A, Yerly S, Combescure C, Swiss HIV Cohort Study
Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy
Magenta L, Bernasconi E, Bucher H, Decosterd L, Cavassini M, Evison J, Vernazza P, Hirschel B, Flepp M, Hasse B, Young J, Richter W, Dell-Kuster S, the Swiss HIV Cohort Study (SHCS). Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy. AIDS Res Hum Retroviruses 2010
Nov 22, 2010Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy
Nov 22, 2010AIDS Res Hum Retroviruses 2010
Magenta L, Bernasconi E, Bucher H C, Decosterd L A, Cavassini M, Evison J, Vernazza Pietro, Hirschel B, Flepp M, Hasse B, Young J, Richter W O, Dell-Kuster S, the Swiss HIV Cohort Study (SHCS)
Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study
Young J, Bucher H, Battegay M, Hirschel B, Vernazza P, Bernasconi E, Cavassini M, Fux C, Rickenbach M, Böni J, Yerly S, Opravil M, Günthard H, Scherrer A, for the Swiss HIV Cohort Study. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Med 2010
Oct 18, 2010Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study
Oct 18, 2010HIV Med 2010
Young J, Bucher Hc, Battegay M, Hirschel B, Vernazza Pietro, Bernasconi E, Cavassini M, Fux Ca, Rickenbach M, Böni J, Yerly S, Opravil M, Günthard Hf, Scherrer Au, for the Swiss HIV Cohort Study
Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study(*)
Ledergerber B, Weber R, Rickenbach M, Furrer H, Hirschel B, Vernazza P, Bernasconi E, Battegay M, Cavassini M, and the Swiss HIV Cohort Study (SHCS). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study(*). HIV Med 2010
Oct 18, 2010Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study(*)
Oct 18, 2010HIV Med 2010
Ledergerber B, Weber R, Rickenbach M, Furrer H, Hirschel B, Vernazza Pietro, Bernasconi E, Battegay M, Cavassini M, and the Swiss HIV Cohort Study (SHCS)
How reliable is an undetectable viral load?
Combescure C, Hirschel B, Vernazza P, Bernasconi E, Battegay M, Rauch A, Furrer H, Cavassini M, Ledergerber B, Vallier N, Swiss HIV Cohort Study. How reliable is an undetectable viral load?. HIV medicine 2009; 10:470-6.
Sep 1, 2009How reliable is an undetectable viral load?
Sep 1, 2009HIV medicine 2009; 10:470-6
Combescure Christophe, Hirschel B, Vernazza Pietro, Bernasconi E, Battegay M, Rauch A, Furrer H, Cavassini M, Ledergerber B, Vallier N, Swiss HIV Cohort Study
Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study
Weber R, Ledergerber B, Schmid P, Bernasconi E, Cavassini M, Hirschel B, Elzi L, Furrer H, Rickenbach M, Huber M, Swiss HIV Cohort Study. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV medicine 2009; 10:407-16.
Aug 1, 2009Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study
Aug 1, 2009HIV medicine 2009; 10:407-16
Weber R, Ledergerber B, Schmid Patrick, Bernasconi E, Cavassini M, Hirschel B, Elzi L, Furrer H, Rickenbach M, Huber M, Swiss HIV Cohort Study
Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study
Wunder D, Furrer H, Mueller B, Bernasconi E, Schmid P, Elzi L, Cavassini M, Hirschel B, Mueller N, Bersinger N, Fux C, Swiss HIV Cohort Study. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV medicine 2008; 9:427-32.
Jul 1, 2008Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study
Jul 1, 2008HIV medicine 2008; 9:427-32
Wunder D M, Furrer H, Mueller B, Bernasconi E, Schmid Patrick, Elzi L, Cavassini M, Hirschel B, Mueller N J, Bersinger N A, Fux C A, Swiss HIV Cohort Study
Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study
Wolbers M, Battegay M, Hirschel B, Bernasconi E, Schmid P, Weber R, Cavassini M, Rickenbach M, Furrer H, Bucher H, Swiss HIV Cohort Study. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV medicine 2008; 9:397-405.
Jul 1, 2008Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study
Jul 1, 2008HIV medicine 2008; 9:397-405
Wolbers M, Battegay M, Hirschel B, Bernasconi E, Schmid Patrick, Weber R, Cavassini M, Rickenbach M, Furrer H, Bucher H C, Swiss HIV Cohort Study
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006
Nguyen A, Hirschel B, Perneger T, Schmid P, Tarr P, Evison J, Opravil M, Battegay M, Bernasconi E, Schiffer V, Calmy A, Swiss HIV Cohort Study. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV medicine 2008; 9:142-50.
Mar 1, 2008Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006
Mar 1, 2008HIV medicine 2008; 9:142-50
Nguyen A, Hirschel B, Perneger T, Schmid Patrick, Tarr P E, Evison J-M, Opravil M, Battegay M, Bernasconi E, Schiffer V, Calmy A, Swiss HIV Cohort Study
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, Wolbers M, Ungsedhapand C, Swiss HIV Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine 2006; 7:404-10.
Sep 1, 2006Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Sep 1, 2006HIV medicine 2006; 7:404-10
Glass T R, Bucher H C, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza Pietro, Weber R, Wolbers M, Ungsedhapand C, Swiss HIV Cohort Study
Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
Bucher H, Battegay M, Minder C, Vernazza P, Bernasconi E, Weber R, Hirschel B, Telenti A, Furrer H, Taffé P, Bichsel M, Swiss HIV Cohort Study. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine 2002; 3:247-53.
Oct 1, 2002Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
Oct 1, 2002HIV medicine 2002; 3:247-53
Bucher H C, Battegay M, Minder C, Vernazza Pietro, Bernasconi E, Weber R, Hirschel B, Telenti A, Furrer H, Taffé P, Bichsel M, Swiss HIV Cohort Study
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
Yerly S, Perrin L, Hirschel B, Rickenbach M, Bru J, Veuthey A, Battegay M, Telenti A, Flepp M, Vernazza P, Chave J, Rizzardi P, Vora S, Swiss HIV Cohort Study. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (London, England) 2001; 15:2287-92.
Nov 23, 2001Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
Nov 23, 2001AIDS (London, England) 2001; 15:2287-92
Yerly S, Perrin L, Hirschel B, Rickenbach M, Bru J P, Veuthey A L, Battegay M, Telenti A, Flepp M, Vernazza Pietro, Chave J P, Rizzardi P, Vora S, Swiss HIV Cohort Study
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study
Boubaker K, Francioli P, Rickenbach M, Opravil M, Egger M, Bernasconi E, Chave J, Boggian K, Hirschel B, Haensel A, Furrer H, Sudre P, Flepp M, Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33:1931-7.
Oct 23, 2001Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study
Oct 23, 2001Clin Infect Dis 2001; 33:1931-7
Boubaker K, Francioli P, Rickenbach M, Opravil M, Egger M, Bernasconi E, Chave J P, Boggian Katia, Hirschel B, Haensel A, Furrer H, Sudre P, Flepp M, Telenti A
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Fellay J, Telenti A, Flepp M, Greub G, Francioli P, Vernazza P, Hirschel B, Battegay M, Furrer H, Bernasconi E, Ledergerber B, Boubaker K, Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-7.
Oct 20, 2001Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Oct 20, 2001Lancet 2001; 358:1322-7
Fellay J, Telenti A, Flepp M, Greub G, Francioli P, Vernazza Pietro, Hirschel B, Battegay M, Furrer H, Bernasconi E, Ledergerber B, Boubaker K, Swiss HIV Cohort Study
HIV transmission after suspension of highly active antiretroviral therapy
Bernasconi E, Vernazza P, Bernasconi A, Hirschel B, Swiss HIV Cohort Study. HIV transmission after suspension of highly active antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999) 2001; 27:209.
Jun 1, 2001HIV transmission after suspension of highly active antiretroviral therapy
Jun 1, 2001Journal of acquired immune deficiency syndromes (1999) 2001; 27:209
Bernasconi E, Vernazza Pietro, Bernasconi A, Hirschel B, Swiss HIV Cohort Study
Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
Battegay M, Hirschel B, Bedoucha V, Morgenthaler S, Jaccard C, Malinverni R, Erb P, Sendi P, Flepp M, Bernasconi E, Vernazza P, Swiss HIV Cohort Study. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. HIV medicine 2001; 2:35-42.
Jan 1, 2001Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
Jan 1, 2001HIV medicine 2001; 2:35-42
Battegay M, Hirschel B, Bedoucha V, Morgenthaler S, Jaccard C, Malinverni R, Erb P, Sendi P, Flepp M, Bernasconi E, Vernazza Pietro, Swiss HIV Cohort Study
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study
Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J, Boggian K, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
Nov 25, 2000Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study
Nov 25, 2000Lancet 2000; 356:1800-5
Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J C, Boggian Katia, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study
Rutschmann O, Perrin L, Leduc D, Fagard C, Bernasconi E, Malinverni R, Telenti A, Ledergerber B, Opravil M, Bucher H, Vernazza P, Hirschel B. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS (London, England) 2000; 14:2145-51.
Sep 29, 2000Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study
Sep 29, 2000AIDS (London, England) 2000; 14:2145-51
Rutschmann O T, Perrin L, Leduc D, Fagard C, Bernasconi E, Malinverni R, Telenti A, Ledergerber B, Opravil M, Bucher H C, Vernazza Pietro, Hirschel B
[HIV superinfection: myth or reality?]
Vernazza P, Bernasconi E, Hirschel B. [HIV superinfection: myth or reality?]. Schweizerische medizinische Wochenschrift 2000; 130:1101-4.
Aug 8, 2000[HIV superinfection: myth or reality?]
Aug 8, 2000Schweizerische medizinische Wochenschrift 2000; 130:1101-4
Vernazza Pietro, Bernasconi E, Hirschel B